Valneva SE to Attend Major Investor Conferences
Valneva SE is gearing up to participate in significant investor conferences that promise to provide insights into its strategic direction and innovative vaccine pipeline. As a leading specialty vaccine company, Valneva is committed to developing vaccines that address critical health needs globally. CEO Thomas Lingelbach and CFO Peter Bühler will represent Valneva at these key events.
Highlights of Upcoming Conferences
At the upcoming TD Cowen 45th Annual Health Care Conference, scheduled for March 3 - 5, the management team will highlight Valneva's compelling vaccine candidates. The conference will also allow for insightful interactions with institutional investors eager to learn more about the company's advancements in vaccine development.
Presentation Details
During this event, Valneva leaders will present on March 4, 2025, at 1:10 PM ET. The presentation will be accessible via a live webcast, enabling both in-person and virtual attendees to engage with Valneva's vision and product pipeline.
Insights into Valneva's Vaccine Pipeline
Valneva's presentation will cover its promising candidates, notably the Lyme disease vaccine VLA15, and delve into its programs targeting Shigella and Zika virus. These initiatives highlight the company's commitment to addressing unmet medical needs through innovative solutions.
Revenue Expectations for 2025
Valneva anticipates generating between €170 million and €180 million in revenue in the upcoming year. This growth is largely attributed to the successful marketing of its current vaccines and the promising trajectory of its development pipeline.
Van Lanschot Kempen Life Sciences Conference
Following the TD Cowen conference, Valneva will also participate in the Van Lanschot Kempen Life Sciences Conference on April 2 - 3. This second event will focus on further establishing relationships with institutional investors who are pivotal in aiding Valneva's mission and objectives.
Meeting with Institutional Investors
During the Van Lanschot Kempen Conference, Valneva encourages interested institutional investors to coordinate meetings with the management team through their banks. This is an excellent opportunity for investors to engage directly with executive leadership.
About Valneva SE
Valneva is a prominent vaccine company that specializes in the development and commercialization of prophylactic vaccines tailored to combat infectious diseases. With a robust portfolio, the company focusses on both innovative and effective vaccine solutions while addressing global health concerns.
With a successful history of advancing vaccines from research and development to market, Valneva currently offers three proprietary travel vaccines, including their pioneering chikungunya vaccine.
Fueling Ongoing Innovation
The revenue generated from Valneva's ongoing commercial business is instrumental in funding further research and development of vaccine candidates. This includes their Lyme disease vaccine, developed in partnership with Pfizer, and a promising tetralent Shigella vaccine, among others.
Valneva’s commitment is to leverage its expertise in vaccine technology to deliver first-class solutions to public health challenges. For more information about their exciting developments and to stay updated, visit Valneva's official website.
Frequently Asked Questions
What events will Valneva SE participate in?
Valneva SE will take part in the TD Cowen 45th Annual Health Care Conference and the Van Lanschot Kempen Life Sciences Conference.
What topics will Valneva discuss at the conferences?
Valneva will present its pipeline of vaccine candidates, including the Lyme disease vaccine VLA15, and discuss anticipated revenues for 2025.
Who will represent Valneva at the conferences?
CEO Thomas Lingelbach and CFO Peter Bühler will represent Valneva at the investor conferences.
What are the expected revenues for Valneva in 2025?
Valneva expects revenues between €170 million and €180 million for the year 2025.
How can investors meet with Valneva management?
Institutional investors can request meetings with Valneva management through their respective banks during the conferences.
